Pharmaceutical company Astellas reported on Tuesday the promotion of Geoff Towle to vice president of Oncology Marketing at Astellas US.
In the escalated role, Towle will be responsible for building Astellas Oncology brands with customers in large and specialty market segments through the development and implementation of innovative marketing methods, reporting to senior vice president of Oncology Business Unit, Mark Reisenauer.
Most recently, Towle was employed as senior director, Oncology Marketing at Astellas, where he led the development of brand strategies, messaging and tactics for XTANDI as well as led four best-in-class launches within Astellas and across the industry based on speed of execution, quality and performance.
At the start of his career, Towle has served in a variety of positions with increasing responsibility at Abbott Laboratories Inc (now AbbVie).
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval